33,113 Shares of Gilead Sciences, Inc. $GILD Bought by Machina Capital S.A.S.

Machina Capital S.A.S. purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 33,113 shares of the biopharmaceutical company’s stock, valued at approximately $4,935,000. Gilead Sciences comprises approximately 0.6% of Machina Capital S.A.S.’s portfolio, making the stock its 28th biggest holding.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Davis Investment Partners LLC increased its stake in shares of Gilead Sciences by 26.9% in the third quarter. Davis Investment Partners LLC now owns 5,128 shares of the biopharmaceutical company’s stock worth $764,000 after buying an additional 1,086 shares during the period. Illinois Municipal Retirement Fund boosted its position in Gilead Sciences by 5.1% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 321,286 shares of the biopharmaceutical company’s stock valued at $47,888,000 after buying an additional 15,533 shares during the period. Knights of Columbus Asset Advisors LLC boosted its position in Gilead Sciences by 4.2% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 114,329 shares of the biopharmaceutical company’s stock valued at $17,041,000 after buying an additional 4,617 shares during the period. Philadelphia Trust Co. boosted its position in Gilead Sciences by 14.3% during the 3rd quarter. Philadelphia Trust Co. now owns 4,347 shares of the biopharmaceutical company’s stock valued at $648,000 after buying an additional 545 shares during the period. Finally, Moneco Advisors LLC grew its holdings in Gilead Sciences by 2.4% in the 3rd quarter. Moneco Advisors LLC now owns 3,913 shares of the biopharmaceutical company’s stock worth $583,000 after acquiring an additional 91 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the transaction, the insider owned 113,684 shares in the company, valued at $17,759,714.48. The trade was a 2.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 9,810 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $175.17, for a total transaction of $1,718,417.70. Following the completion of the transaction, the chief executive officer directly owned 551,683 shares of the company’s stock, valued at approximately $96,638,311.11. The trade was a 1.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 242,709 shares of company stock worth $39,503,427. 0.30% of the stock is currently owned by company insiders.

Latest Gilead Sciences News

Investors following GILD have been watching these news items:

• Positive Sentiment: Gilead reported PURPOSE 5 results showing twice-yearly injectable lenacapavir outperformed daily oral HIV prevention on persistence, with no HIV infections in the injectable group. The findings could strengthen the long-term opportunity for its HIV prevention franchise. Gilead Sciences Posts PURPOSE 5 Win As HIV Shot Beats Daily Pills
• Neutral Sentiment: Valuation views are mixed after GILD’s substantial multi-year advance: one analysis sees the shares as undervalued based on cash-flow potential, while another considers them fully valued after the rally. This may make further gains more dependent on continued execution. Gilead Stock Still Looks Undervalued On Its 205% Run Gilead Looks Fully Valued
• Negative Sentiment: Potential U.S. drug-price negotiations pose a near-term risk to Gilead’s revenue, adding a policy overhang even as its clinical and commercial prospects improve. Drug Pricing Risks As Washington Turns Up Heat

Gilead Sciences Stock Performance

Shares of GILD stock opened at $169.73 on Thursday. The firm has a market capitalization of $210.52 billion, a price-to-earnings ratio of -53.71 and a beta of 0.35. The stock has a fifty day moving average of $154.40 and a 200 day moving average of $141.51. Gilead Sciences, Inc. has a 52 week low of $116.88 and a 52 week high of $176.58. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The business had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. During the same period in the previous year, the firm earned $2.47 EPS. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. As a group, research analysts expect that Gilead Sciences, Inc. will post -0.98 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. Gilead Sciences’s payout ratio is presently -103.80%.

Wall Street Analyst Weigh In

GILD has been the topic of a number of analyst reports. TD Cowen boosted their price objective on shares of Gilead Sciences from $160.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Scotiabank increased their target price on shares of Gilead Sciences from $177.00 to $200.00 and gave the stock a “sector outperform” rating in a report on Friday, October 30th. Leerink Partners cut Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Barclays reduced their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. Finally, Royal Bank Of Canada boosted their price target on Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a report on Friday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $170.15.

Gilead Sciences Profile

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.